Recently, Chemical.AI announced the completion of a nearly 100-million-yuan Series B financing round, led by Changjiang Securities Innovation Investment (Hubei) Co., Ltd., with participation from CE Innovation Capital.
It is reported that the proceeds of this round of financing will be used to promote the development of Chemical.AI in the AI pharmaceuticals sector, accelerate the iteration speed of Chemical.AI's retrosynthesis platform technology and automation technology innovation, thereby comprehensively enhancing the efficiency of chemical synthesis empowerment.
Chemical.AI is a research and development technology company that empowers chemical synthesis through AI. By leveraging artificial intelligence technology and chemical big data, it has developed tools that significantly improve the efficiency of chemical research. It is committed to building an intelligent compound planning platform to shape the future of chemistry. In 2021, Chemical.AI established an automated laboratory (ChemAILab) in Shanghai, combining AI technology and big data-driven chemical synthesis algorithms with robotics to break through the efficiency bottleneck of current synthetic chemistry services, providing the industry with more professional and efficient chemical synthesis services.
Chemical.AI has accumulated extensive experience in the niche field of chemical synthesis and achieved remarkable results in the retrosynthesis phase. Its ChemAIRS retrosynthesis platform, as a leading AI-assisted system for synthetic route design, leverages AI and big data to design synthetic routes for organic molecules. This helps companies achieve digital transformation and accelerate drug development efficiency. To date, Chemical.AI has successfully provided technical services to several well-known domestic and international pharmaceutical companies and CROs, engaging in deep collaboration in areas such as retrosynthetic route design, synthetic feasibility assessment, forward synthetic molecular libraries, and process route optimization.
Chemical AI CEO Ning Xia stated: "The application of AI and automation in the field of chemical synthesis is rapidly developing and maturing. As a company that has always focused on this field, Chemical AI will further develop an intelligent chemical synthesis platform that integrates data, algorithms, and automation, empowering partners in pharmaceuticals, materials, and other fields. This round of financing will be used for continuous technological innovation and market promotion both in China and internationally."